EGFR and non-small cell lung carcinoma: Furthermore, new generations of EGFR-TKIs have been introduced since the first-generation drug, gefitinib (Iressa®), was introduced in 2003 and first approved by the FDA to treat NSCLC in August of 2014 [7].